Exosome-Based Drug Targeting
Non-invasive, encapsulated drugs delivered via engineered exosomes across the BBB. Offers
precise targeting with low immunogenicity.
Exosome-based targeting is reshaping intercellular communication and delivery. Exosomes, natural nanocarriers represent a transformative shift in precision therapeutics offering unparalleled biocompatibility, stability, efficient transport and tissue specific homing leveraging the body’s communication system.
AI-Driven Model to identify molecules for novel brain targets
Utilizing AI enables faster identification of potential small-molecule drug candidates for novel targets.
Patient- Centric Platform/Model
Help to identify response biomarkers and combinatorial strategies.
Enhancing treatment efficacy while minimizing side effects for better patient outcomes
Faster/Accelerated Clinical POC with Reduced Cost
Taking advantage of Founders’ network in different geographies to get clinical data and possible
approval with significantly reduced cost and time.
We have identified a clinically validated compound targeting a novel pathway in brain cancers.
To overcome the challenges of brain delivery, we are developing a brain-specific exosome-based targeting strategy that enables efficient transport of the molecule across the blood–brain
barrier (BBB). This approach is designed to enhance therapeutic efficacy in brain tumors while minimizing off-target toxicities in peripheral organs.
In parallel, we have developed a proprietary, humanized BBB platform that faithfully mimics the physiological blood–brain barrier using human astrocytes, pericytes, and primary endothelial cells. This platform enables selective and predictive assessment of compound transport into brain and tumor compartments.
Our machine learning–driven discovery engine further strengthens this platform by identifying compounds with high BBB permeability. These predictions allow us to prioritize a focused set of molecules for experimental validation using our human BBB model. Leveraging these insights, we can rationally modify drug candidates to optimize brain delivery and selectively target diseased regions of the brain.